Module 3: diagnosis – rapid diagnostics for tuberculosis detection
Module 3: diagnosis –
rapid diagnostics for tuberculosis
detection
Module 3 : Diagnosis -Rapid Diagnostics for tuberculosis detection, World Health Organization (WHO)
In this study, an attempt is made to present the characteristics of an ecosystem for the successful development of indigenous diagnostic technology, called ‘TrueNat’, which have dealt the context-specific challenges associated with Tuberculosis (TB) diagnostics and has been validated by the Indian Council of Medical Research for addressing the specific challenges related to COVID-19 testing.
Decentralized molecular testing is gaining ground for SARS-CoV-2 diagnosis in India. Due inpart to a robust anti-tuberculosis campaign, the testing modality has made inroads into the country'scomplex and tiered healthcare system during the past decade. Now, decentralized platforms from firms likeMolBio Diagnostics and Cepheid, as well as newcomer Tata Group, are starting to play a significant role inCOVID-19 diagnostic testing in India as well.
NEW YORK (GenomeWeb) – MolBio, a Goa, India-based molecular diagnostics manufacturer, is bringing tuberculosis testing closer to patients in its home country, potentially competing with imported testing. MolBio's point-of-care real-time PCR system and infectious disease assays are currently commercially available in India, and the Foundation for Innovation of New Diagnostics (FIND) is now assisting the firm with clinical trials of its TB test system prior to review by the World Health Organization for potential prequalification.
